Streetbeat News

Products Services

DRUG

Bright Minds Biosciences is set to begin a Phase 2 clinical trial for BMB-101, targeting drug-resistant epilepsy disorders. The company has secured financial stability until 2026 and will host a webcast on September 25th.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:06 pm

NOC

RTX

Raytheon, a business of RTX, and Northrop Grumman have successfully completed a static fire test of an advanced long-range solid rocket motor. This test, conducted at Northrop Grumman's Allegany Ballistics Laboratory, validates the design maturity and performance of the rocket motor, which is intended for hypersonic applications.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:06 pm

MNPR

Monopar Therapeutics has released early human clinical data from its ongoing open-label Phase 1 imaging and dosimetry study of MNPR-101-Zr. This study is crucial for understanding the potential of MNPR-101-Zr in medical imaging.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:05 pm

DXR

Daxor Corporation's blood volume analysis (BVA) technology has been highlighted in a review published in Cardiorenal Medicine. The review emphasizes BVA's role in improving care and outcomes for cardiorenal syndrome by enhancing precision in diuretic and red cell therapies, leading to more personalized treatment.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:02 pm

M

Macy's has launched a new contemporary menswear brand, Mode of One, focusing on individuality and style expression. This brand is part of Macy's strategy to enhance its private brand offerings.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:02 pm

NICE

Arrow XL, a UK delivery specialist, has chosen NICE CXone to enhance its digital transformation, resulting in increased efficiency and cost savings. NICE's AI-powered platform will support Arrow XL's growth by unifying communications for its delivery operations.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:02 pm

VERA

Vera Therapeutics has completed enrollment for the primary endpoint in its Phase 3 ORIGIN 3 trial of atacicept for IgAN, with results expected in Q2 2025. The company will also present data from a Phase 2b trial in Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:01 pm

GLD

NVDA

SPY

USO

U.S. markets closed higher with strong gains in the technology sector, led by Nvidia. Inflation data showed a 0.2% increase in CPI for August. Asian markets were mixed, while European markets advanced. Crude oil and gold prices rose due to disruptions in U.S. Gulf production.

Portfolio Pulse from Akanksha Bakshi

September 12, 2024 | 12:00 pm

WKSP

Worksport Ltd (NASDAQ:WKSP) reported a significant increase in sales for August 2024, reaching $1.21 million, which boosts their Annual Recurring Revenue to $14.56 million. The company is on track to exceed its 2024 revenue guidance and aims for cash flow positivity by 2025. Worksport's CEO highlights the company's undervaluation and potential for growth, especially with upcoming product lines like AL4, SOLIS, and COR. Despite positive news, WKSP stock closed 3.34% lower at $0.4926.

Portfolio Pulse from Anusuya Lahiri

September 12, 2024 | 12:00 pm

AIBD

AIBU

AMD

NVDA

NVIDIA and AMD stocks rose significantly amid potential export approvals to Saudi Arabia and interest in OpenAI's equity raise. Direxion's AI and Big Data Bull and Bear ETFs offer traders opportunities to capitalize on AI market trends.

Portfolio Pulse from Joshenomoto@benzinga.com

September 12, 2024 | 11:49 am